REG - Oxford Biomedica PLC - Director/PDMR Shareholding

Oxford BioMedicaAnnouncement

13/08/2018 10:50

RNS Number : 6123X
Oxford Biomedica PLC
13 August 2018
 


 
 
 
 
 
 
PDMR Dealings / Market Share Sale
 
Oxford, UK - 13 August 2018: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, today announces that Kyriacos Mitrophanous, Chief Scientific Officer, exercised 13,395 options at 50p ("Ordinary Shares") in the Company on 09 August 2018 and sold all the resulting shares at 904.416p. Following this transaction Kyriacos Mitrophanous holds 164,332 options in the Company.
 
375 options were exercised at 101.5p and all the resulting shares were sold at 904.416p by Kyriacos Mitrophanous wife (Pippa Radcliffe) and are therefore considered a beneficial holding of Kyriacos Mitrophanous.
 
The issued share capital of the Company is 65,752,788 ordinary shares of 50 pence each.
The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares purchased.
 
 



 1.


Details of the person discharging material responsibilities/person closely                 associated
 




 a.


Name


 Kyriacos Mitrophanous
 




 2.


Reason for the notification
 




 a.


Position/status


 Chief Scientific Officer
 




 b.


Initial notification /amendment


 Initial notification
 




3.


Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor
 




 a.


Name


 Oxford BioMedica plc
 




 b.


Legal Entity Identifier


 213800S1GVQNXQ15K851
 




4.


Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
 




 a.


Description of the financial instrument, type of instrument identification code


 Ordinary Shares of 50p each
 
 
 ISIN: GB00BDFBVT43
 




b.


Nature of the transaction


 Exercise of Options
 




c.


Currency


 GBP - British Pound
 




d.


Price(s) and volume(s)


 
Price(s)
 


 
Volume(s)




 


 


£0.50


13,395




e.


Aggregated information
·      Aggregated volume
·      Price
·      Aggregated total
 


 
13,395
 
 £0.50
 £6,697.5
 




f.


Date of the transaction


 2018-08-13
 




g.


Place of the transaction


 London Stock Exchange, Main Market (XLON)
 



 



 1.


Details of the person discharging material responsibilities/person closely                 associated
 




 a.


Name


 Kyriacos Mitrophanous
 




 2.


Reason for the notification
 




 a.


Position/status


 Chief Scientific Officer
 




 b.


Initial notification /amendment


 Initial notification
 




3.


Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor
 




 a.


Name


 Oxford BioMedica plc
 




 b.


Legal Entity Identifier


 213800S1GVQNXQ15K851
 




4.


Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
 




 a.


Description of the financial instrument, type of instrument identification code


 Ordinary Shares of 50p each
 
 
 ISIN: GB00BDFBVT43
 




b.


Nature of the transaction


 Disposal
 




c.


Currency


 GBP - British Pound
 




d.


Price(s) and volume(s)


 
Price(s)
 


 
Volume(s)




 


 


£9.04416


13,395




e.


Aggregated information
·      Aggregated volume
·      Price
·      Aggregated total
 


 
13,395
 
 £9.04416
 £121,146.52
 




f.


Date of the transaction


 2018-08-13
 




g.


Place of the transaction


 London Stock Exchange, Main Market (XLON)
 



 
 



 1.


Details of the person discharging material responsibilities/person closely                 associated
 




 a.


Name


 Pippa Radcliffe
 




 2.


Reason for the notification
 




 a.


Position/status


 Person closely associated with Kyriacos Mitrophanous, Chief Scientific Officer
 




 b.


Initial notification /amendment


 Initial notification
 




3.


Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor
 




 a.


Name


 Oxford BioMedica plc
 




 b.


Legal Entity Identifier


 213800S1GVQNXQ15K851
 




4.


Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
 




 a.


Description of the financial instrument, type of instrument identification code


 Ordinary shares of 50p each
 
 
 ISIN: GB00BDFBVT43
 




b.


Nature of the transaction


 Purchase of ordinary shares
 




c.


Currency


 GBP - British Pound
 




d.


Price(s) and volume(s)


 
Price(s)
 


 
Volume(s)




£1.015


375




 


 




e.


Aggregated information
·      Aggregated volume
·      Price
·      Aggregated total
 


 
 375
 
 £101.5
 £380.63
 




f.


Date of the transaction


 2018-08-13
 




g.


Place of the transaction


 London Stock Exchange, Main Market (XLON)
 



 
 



 1.


Details of the person discharging material responsibilities/person closely                 associated
 




 a.


Name


 Pippa Radcliffe
 




 2.


Reason for the notification
 




 a.


Position/status


 Person closely associated with Kyriacos Mitrophanous, Chief Scientific Officer
 




 b.


Initial notification /amendment


 Initial notification
 




3.


Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor
 




 a.


Name


 Oxford BioMedica plc
 




 b.


Legal Entity Identifier


 213800S1GVQNXQ15K851
 




4.


Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
 




 a.


Description of the financial instrument, type of instrument identification code


Disposal
 




b.


Nature of the transaction


 Purchase of ordinary shares
 




c.


Currency


 GBP - British Pound
 




d.


Price(s) and volume(s)


 
Price(s)
 


 
Volume(s)




£9.04416


375




 


 




e.


Aggregated information
·      Aggregated volume
·      Price
·      Aggregated total
 


 
 375
 
 £9.04416
 £3,391.5
 




f.


Date of the transaction


 2018-08-13
 




g.


Place of the transaction


 London Stock Exchange, Main Market (XLON)
 



 
 
                                                                                                                               
 
 
 
-Ends-
 



For further information, please contact:


 




 
Oxford BioMedica plc:
John Dawson,  Chief Executive Officer
Stuart Paynter, Chief Financial Officer


 
Tel: +44 (0)1865 783 000




 
Financial and corporate communications enquiries:
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal/Olivia Manser/Laura Thornton
 


 
Tel: +44 (0)20 3709 5700



 
Notes for editors
 
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, GSK, Orchard Therapeutics, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 320 people. Further information is available at www.oxfordbiomedica.co.uk.




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHGCGDILSBBGIX